老年晚期非小细胞肺癌患者免疫检查点抑制剂研究进展  

Research progress on immune checkpoint inhibitors in older patients with advanced non-small cell lung cancer

作　　者：袁月 唐敏[1] 李琳[1,2] Yuan Yue;Tang Min;Li Lin(Department of Oncology,Beijing Hospital National Center of Gerontology Institute of Geriatric Medicine,Chinese Academy of Medical Science,Beijing 100730,China;Graduate School of Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]北京医院肿瘤内科国家老年医学中心中国医学科学院老年医学研究所,北京100730 [2]北京协和医学院研究生院中国医学科学院,北京100730

出　　处：《中华老年医学杂志》2022年第3期360-365,共6页Chinese Journal of Geriatrics

摘　　要：肺癌是最常见的老年恶性肿瘤之一,以免疫检查点抑制剂为代表的免疫治疗利用机体免疫系统达到有效的抗肿瘤效应。在晚期非小细胞肺癌(NSCLC)患者中,免疫检查点抑制剂单药治疗及联合治疗已成为重要的治疗手段,现对免疫检查点抑制剂类药物在老年晚期NSCLC患者中应用的效果、不良反应、超进展情况进行综述,为老年NSCLC免疫治疗策略提供参考。Lung cancer is one of the most common malignant neoplastic diseases in the elderly.Immunotherapy represented by immune checkpoint inhibitors mobilizes the body's immune system to achieve antitumor effects.Immune checkpoint inhibitors and their combination with other drugs have played an increasingly important role in the treatment of patients with advanced non-small cell lung cancer.In this review,we summarize the therapeutic effects,adverse reactions and hyperprogressive disease of immune checkpoint inhibitors in the elderly with advanced non-small cell lung cancer,in order to provide insight on immunotherapy strategies for non-small cell lung cancer in the elderly.

关 键 词：肺癌 非小细胞 免疫抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]